Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa
  • Amsterdam
  • Berlin
  • Brussels
  • Copenhagen
  • Danske Bank
  • Denmark
  • DFDS
  • DSV
  • Faroe Islands
  • Greenland
  • Helsinki
  • LEGO
  • Mærsk
  • Novo Nordisk
  • Ørsted
  • Oslo
  • Riga
  • Stockholm
  • Tallinn
  • Vestas Wind Systems
  • Vilnius
  • Warsaw
Denmark
  • Europe
    • FR
    • DE
    • IT
    • ES
    • PL
    • BE
    • NL
    • LU
    • CH
    • NO
    • SE
    • FI
    • EE
    • LV
    • LT
  • Denmark
    • Faroe Islands
    • Greenland
    • Copenhagen
  • Business
    • Mærsk
    • Novo Nordisk
    • DSV
    • Ørsted
    • Danske Bank
    • Vestas Wind Systems
    • LEGO
    • DFDS
  • Nordics
    • Stockholm
    • Oslo
    • Helsinki
  • Baltics
    • Tallinn
    • Riga
    • Vilnius
  • Benelux
    • Brussels
    • Amsterdam
  • Warsaw
  • Berlin
  • NATO
  • UK
  • US
  • Africa

Browsing Tag

GLP-1

25 posts
NNovo Nordisk
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
Read More

Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes

  • 2026-04-23
PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged…
NNovo Nordisk
Novo Nordisk's Blood Disorder Breakthrough Offers a Lifeline Amid GLP-1 Gloom
Read More

Novo Nordisk’s Blood Disorder Breakthrough Offers a Lifeline Amid GLP-1 Gloom

  • 2026-04-21
Novo Nordisk’s etavopivat succeeds in Phase 3 sickle cell trial, cutting painful crises by 27%. This diversifies its…
NNovo Nordisk
Novo Nordisk's Clinical Win and Competitive Crossroads
Read More

Novo Nordisk’s Clinical Win and Competitive Crossroads

  • 2026-04-20
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…
NNovo Nordisk
Novo Nordisk's Clinical Win and Competitive Crossroads
Read More

Novo Nordisk’s Clinical Win and Competitive Crossroads

  • 2026-04-20
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…
NNovo Nordisk
Novo Nordisk's Price and Pill Playbook in a Shifting GLP-1 Arena
Read More

Novo Nordisk’s Price and Pill Playbook in a Shifting GLP-1 Arena

  • 2026-04-11
Novo Nordisk defends obesity drug franchise with new 7.2mg Wegovy dose and positive oral semaglutide data, despite stock…
NNovo Nordisk
Wegovy Subscription Launched—Here’s How Much It Could Save Users A Year
Read More

Wegovy Subscription Launched—Here’s How Much It Could Save Users A Year

  • 2026-03-31
Topline Novo Nordisk has launched a multi-month subscription program meant to lower the price of the weight loss…
NNovo Nordisk
Novo Nordisk Shares Face Sustained Decline: Analysis and Outlook - News and Statistics
Read More

Novo Nordisk Shares Face Sustained Decline: Analysis and Outlook – News and Statistics

  • 2026-03-21
Mar 20, 2026 Shares of Danish drugmaker Novo Nordisk have been in a full-blown tailspin over the past…
NNovo Nordisk
Novo Nordisk eyes next-gen anti-obesity drugs as generics enter market – ThePrint – Select
Read More

Novo Nordisk eyes next-gen anti-obesity drugs as generics enter market – ThePrint – Select

  • 2026-03-21
New Delhi: Vikrant Shrotriya is not particularly troubled by the generics. As Semaglutide—the active ingredient in diabetes and…
NNovo Nordisk
Novo Nordisk's Patent Expires, Indian Pharma Lines Up for Ozempic-Like Weight-Loss Drugs – Outlook Business
Read More

Novo Nordisk’s Patent Expires, Indian Pharma Lines Up for Ozempic-Like Weight-Loss Drugs – Outlook Business

  • 2026-03-20
Other companies, including Divi’s Laboratories, Dr. Reddy’s Laboratories, Cipla Limited, Sun Pharmaceutical Industries, Zydus Lifesciences, Torrent Pharmaceuticals, and…
NNovo Nordisk
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis Growth - News and Statistics
Read More

Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis Growth – News and Statistics

  • 2026-03-19
Mar 18, 2026 According to a report from Yahoo Finance, Pfizer and Novo Nordisk are among the largest…
NNovo Nordisk
New Research Bolsters Case for Long-Term Use of Novo Nordisk's GLP-1 Drugs
Read More

New Research Bolsters Case for Long-Term Use of Novo Nordisk’s GLP-1 Drugs

  • 2026-03-19
New research shows discontinuing Wegovy/Ozempic leads to weight regain and a 22% higher heart attack/stroke risk, strengthening the…
NNovo Nordisk
Novo Nordisk & Hims & Hers: Supply Deal for Ozempic and Wegovy - News and Statistics
Read More

Novo Nordisk & Hims & Hers: Supply Deal for Ozempic and Wegovy – News and Statistics

  • 2026-03-16
Mar 16, 2026 Pharmaceutical firm Novo Nordisk and telehealth provider Hims & Hers Health have entered into a…
Denmark
www.europesays.com